See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Baseball
Natural Disasters
Trade War
Donald Trump
Social Media
Floods
Housing
Taxes
Tennis
Artificial Intelligence
Trade
Published • loading... • Updated

Lilly study data reinforce potential of new kind of heart drug

Summary by biopharmadive.com
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a cardioprotective benefit won’t be answered until Phase 3 tests read out.

1 Articles

All
Left
Center
1
Right
biopharmadive.combiopharmadive.com
Center

Lilly study data reinforce potential of new kind of heart drug

Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a cardioprotective benefit won’t be answered until Phase 3 tests read out.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news in on Monday, March 31, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Amgen

Amgen

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal